The role of the immune system in the physiopathology of osteoporosis

Clinical Cases in Mineral and Bone Metabolism

Volumn 9, Issue 2, 2012, Pages 85-88

  Cagnetta, Valentina ^a   Patella, Vittorio ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

B cells; Cytokines; Immune system; Osteoclast; Osteoporosis; T cells

Indexed keywords

ESTROGEN;

CYTOKINE PRODUCTION; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; SHORT SURVEY;

EID: 84867359182     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (55)

1. Raisz LG, Kream BE, Lorenzo JA, et al. Metabolic bone disease 2002. In: Davies TF, Larsen PR, Kronenberg HM, eds. Williams textbook of endocrinology. Philadelphia: W.B. Saunders; 1373.
2. Rosenberg HF, Gallin JI, Paul WE. Inflammation 1999. In: Paul WE, ed. Fundamental immunology. Philadelphia: Lippincott-Raven; 1051.
3. Horowitz MC, Lorenzo J. Local regulators of bone: IL-1, TNF, and lymphotoxin, interferon gamma, IL-8, IL-10, IL-4, the LIF/IL-6 family and additional cytokines. Principals of bone biology J. Academic Press. San Diego, California, USA. 1996;961-977.
4. Weitzmann MN, Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann N Y Acad Sci 2007;1116:360-375. (Pubitemid 350274346)
5. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007;28:521-574. (Pubitemid 47236336)
6. Roato I, Brunetti G, Gorassini E, et al. IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS One 2006;1: e124.
7. Porter VR, Greendale GA, Schocken M, et al. Immune effects of hormone replacement therapy in post- menopausal women. Exp Gerontol 2001; 36:311-326. (Pubitemid 32162484)
8. D'Amelio P, Grimaldi A, Di Bella S, et al. Estrogen deficiency increases osteoclastogenesis up- regulating T cells activity: a key mechanism in osteoporosis. Bone 2008;43:92-100.
9. Cenci S, Toraldo G, Weitzmann MN, et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003;100:10405-10410. (Pubitemid 37071891)
10. Adamski J, Ma Z, Nozell S, Benveniste EN. 17 beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter. Mol Endocrinol 2004;18:1963-1974. (Pubitemid 39006501)
11. Roggia C, Gao Y, Cenci S, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001;98:13960-13965. (Pubitemid 33116006)
12. Gao Y, Qian WP, Dark K, et al. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci USA 2004;101:16618-16623. (Pubitemid 39557762)
13. Roggia C, Tamone C, Cenci S, et al. Role of TNF-alpha producing T-cells in bone loss induced by estrogen deficiency. Minerva Med 2004;95:125-132. (Pubitemid 38833201)
14. Boss JM, Jensen PE. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr Opin Immunol 2003;15:105-111. (Pubitemid 35454200)
15. Kim JH, Kim K, Youn BU, et al. MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OS-CAR. Cell Signal 2010;22:1341-1349.
16. Mueller RB, Skapenko A, Grunke M, et al. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. Arthritis Rheum 2005;52:451-460. (Pubitemid 40216309)
17. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111:1221-1230. (Pubitemid 36519939)
18. Nagarajan UM, Bushey A, Boss JM. Modulation of gene expression by the MHC class transactivator. J Immunol 2002;169:5078-5088. (Pubitemid 35217177)
19. Li Y, Toraldo G, Li A, et al. B cell and T cell are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007; 109: 3839-3848. (Pubitemid 46641735)
20. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055. (Pubitemid 33131929)
21. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
22. Horwood NJ, Kartsogiannis V, Quinn JM, et al. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999;265:144-150.
23. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
24. Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12. (Pubitemid 30026926)
25. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111:1221-1230. (Pubitemid 36519939)
26. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
27. Kim N, Odgren PR, Kim DK, et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000;97:10905-10910.
28. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-3561. (Pubitemid 30645409)
29. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymphnode development. Genes Dev 1999;13:2412-2424. (Pubitemid 29453612)
30. Pacifici R, Brown C, Puscheck E, et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 1991;88:5134-5138. (Pubitemid 21914698)
31. Hotokezaka H, Sakai E, Ohara N, et al. Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-alpha, lipopolysaccharide, or peptidoglycan. J Cell Biochem 2007;101:122-134. (Pubitemid 46652578)
32. Wei S, Kitaura H, Zhou P, et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005;115:282-290. (Pubitemid 40385470)
33. Takayanagi H, Ogasawara K, Hida S, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000;408:600-605.
34. Sato K, Satoh T, Shizume K, et al. Prolonged decrease of serum calcium concentration by murine gamma-interferon in hypercalcemic, human tumor (EC-GI)bearing nude mice. Cancer Res 1992;52:444-449.
35. Tohkin M, Kakudo S, Kasai H, et al. Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK). Cancer Immunol Immunother 1994;39:155-160. (Pubitemid 24298388)
36. Gao Y, Grassi F, Ryan MR, et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007;117:122-132. (Pubitemid 46048459)
37. Arnoldi J, Gerdes J, Flad HD. Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy. Am J Pathol 1990;137:749-753. (Pubitemid 20337789)
38. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990;144:3347-3353. (Pubitemid 20146364)
39. Cannon GW, Pincus SH, Emkey RD, et al. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1989;32:964-973. (Pubitemid 19218375)
40. Veys EM, Menkes CJ, Emery P. A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1997;40:62-68. (Pubitemid 27044037)
41. Mann GN, Jacobs TW, Buchinsky FJ, et al. Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia. Endocrinology 1994;135:1077-1083.
42. Takayanagi H, Kim S, Taniguchi T. Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res 2002; 4 Suppl 3:S227-S232.
43. Pacifici R. Estrogen deficiency, T cells and bone loss. Cell Immunol 2008;252:68-80.
44. Toraldo G, Roggia C, Qian WP, et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 2003;100:125-130. (Pubitemid 36078040)
45. Weitzmann MN, Roggia C, Toraldo G, et al. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002;110:1643-1650. (Pubitemid 35424242)
46. D'Amelio P, Grimaldi A, Bernabei P, et al. Immune system and bone metabolism: Does thymectomy influence post menopausal bone loss in human? Bone 2006;39:658-665. (Pubitemid 44149278)
47. Ryan MR, Shepherd R, Leavey JK, et al. An IL- 7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci USA 2005;102:16735-16740. (Pubitemid 41688846)
48. Gendron S, Boisvert M, Chetoui N, Aoudjit F. Alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteo- clastogenic function. Immunology 2008;125:359-369.
49. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309.
50. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-2682. (Pubitemid 44833343)
51. Cutler CW, Teng YT. Oral mucosal dendritic cells and peri- odontitis: many sides of the same coin with new twists. Periodontol 2000 2007;45:35-50.
52. Alnaeeli M, Park J, Mahamed D, et al. Dendritic cells at the osteoimmune interface: implications for inflammation induced bone loss. J Bone Miner Res 2007;22:775-780. (Pubitemid 351339736)
53. Alnaeeli M, Teng YT. Dendritic cells: a new player in osteoimmunology. Curr Mol Med 2009;9:893-910.
54. Han X, Lin X, Seliger AR, et al. Expression of receptor activator of nuclear factor-kappaB ligand by B cells in response to oral bacteria. Oral Microbiol Immunol 2009;24:190-196.
55. Chiu YG, Shao T, Feng C, et al. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther 2010;12: R14.